Expertise in
20
conditions

Dr. Bhavana Konda

Oncology
Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, 
Columbus, OH 
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, 
Columbus, OH 

Overview

Bhavana Konda is an Oncologist practicing medicine in Columbus, Ohio.

Dr. Konda is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Thyroid Cancer, Anaplastic Thyroid Cancer, Liver Embolization, and Pancreaticoduodenectomy.

She is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 7 clinical trials. Dr. Konda is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System
Genesis Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Ohio State Martha Morehouse Outpatient Care
2050 Kenny Rd, Columbus, OH 43221

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Lutetium Lu 177 Dotatate, Triapine
Study Phase: Phase 1
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drugs: Sorafenib, Everolimus
Study Phase: Phase 2
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Lenvatinib, Lenvatinib Mesylate, Pembrolizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

66 Total Publications

Bronchoscopic photodynamic therapy for endobronchial metastatic papillary thyroid carcinoma causing lobar airway obstruction: a case report.
Bronchoscopic photodynamic therapy for endobronchial metastatic papillary thyroid carcinoma causing lobar airway obstruction: a case report.
Journal: Annals of translational medicine
Published: March 23, 2026
Similar Doctors
Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Osu Medical Center

320 W 10th Ave, 
Columbus, OH 
 (1.0 miles away)
614-293-8629
Languages Spoken:
English
See accepted insurances

Manisha Shah is an Oncologist practicing medicine in Columbus, Ohio. Dr. Shah is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Thyroid Cancer, Medullary Thyroid Carcinoma, Pancreaticoduodenectomy, and Liver Embolization.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
 (1.0 miles away)
614-366-7744
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Carbone is an Oncologist practicing medicine in Columbus, Ohio. Dr. Carbone is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy. Dr. Carbone is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (0.9 miles away)
614-293-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alice Mims is an Oncologist practicing medicine in Columbus, Ohio. Dr. Mims is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration. Dr. Mims is currently accepting new patients.

Frequently Asked Questions about Dr. Bhavana Konda

How do I make an appointment with Dr. Bhavana Konda?

You can book an appointment with Dr. Bhavana Konda by calling their office at 614-293-3890. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bhavana Konda a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bhavana Konda is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bhavana Konda specialize in?

While Dr. Bhavana Konda is a Oncology, they have specific expertise in Neuroendocrine Tumor, Thyroid Cancer, and Anaplastic Thyroid Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bhavana Konda participate in research or clinical trials?

Yes. Dr. Bhavana Konda has published 66 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Dr. Bhavana Konda's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bhavana Konda accept my insurance?

Dr. Bhavana Konda accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-3890 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Konda's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 10 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile